Ute Essner

461 total citations
21 papers, 333 citations indexed

About

Ute Essner is a scholar working on Pharmacology, Pathology and Forensic Medicine and Physiology. According to data from OpenAlex, Ute Essner has authored 21 papers receiving a total of 333 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pharmacology, 9 papers in Pathology and Forensic Medicine and 7 papers in Physiology. Recurrent topics in Ute Essner's work include Multiple Sclerosis Research Studies (8 papers), Pain Mechanisms and Treatments (5 papers) and Botulinum Toxin and Related Neurological Disorders (5 papers). Ute Essner is often cited by papers focused on Multiple Sclerosis Research Studies (8 papers), Pain Mechanisms and Treatments (5 papers) and Botulinum Toxin and Related Neurological Disorders (5 papers). Ute Essner collaborates with scholars based in Germany, Spain and United States. Ute Essner's co-authors include Michael A. Ueberall, Gerhard Mueller-Schwefe, M. Marinelli, Carlos Vila, Arnd Lentschat, Michael A. Überall, T. Henze, R. Maleßa, Uwe K. Zettl and Peter Flachenecker and has published in prestigious journals such as SHILAP Revista de lepidopterología, Value in Health and Dementia and Geriatric Cognitive Disorders.

In The Last Decade

Ute Essner

20 papers receiving 314 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ute Essner Germany	9	216	87	68	52	43	21	333
Alena Novotná Czechia	4	361 1.7×	155 1.8×	135 2.0×	67 1.3×	99 2.3×	7	522
Senthy Sellaturay United Kingdom	6	304 1.4×	46 0.5×	20 0.3×	75 1.4×	119 2.8×	13	432
Zdeněk Ambler Czechia	5	347 1.6×	204 2.3×	172 2.5×	31 0.6×	88 2.0×	16	558
Linda Mancione United States	8	92 0.4×	59 0.7×	133 2.0×	86 1.7×	38 0.9×	12	483
Douglas Lamounier de Almeida Brazil	6	182 0.8×	53 0.6×	9 0.1×	67 1.3×	60 1.4×	8	326
Wilson Luíz Sanvito Brazil	7	376 1.7×	114 1.3×	37 0.5×	35 0.7×	192 4.5×	42	586
P.J. Toomey United Kingdom	4	268 1.2×	19 0.2×	57 0.8×	112 2.2×	82 1.9×	4	361
Ruben Olmedo United States	9	242 1.1×	24 0.3×	43 0.6×	20 0.4×	104 2.4×	12	404
James M. Nichols United States	6	194 0.9×	23 0.3×	9 0.1×	40 0.8×	40 0.9×	15	302
Jongbae J. Park United States	15	129 0.6×	49 0.6×	44 0.6×	57 1.1×	21 0.5×	23	459

Countries citing papers authored by Ute Essner

Since Specialization

Citations

This map shows the geographic impact of Ute Essner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ute Essner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ute Essner more than expected).

Fields of papers citing papers by Ute Essner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ute Essner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ute Essner. The network helps show where Ute Essner may publish in the future.

Co-authorship network of co-authors of Ute Essner

This figure shows the co-authorship network connecting the top 25 collaborators of Ute Essner. A scholar is included among the top collaborators of Ute Essner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ute Essner. Ute Essner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Haupts, M., Ute Essner, & Mathias Mäurer. (2024). Patient-reported benefits from nabiximols treatment in multiple sclerosis-related spasticity exceed conventional measures. Neurodegenerative Disease Management. 14(1). 11–20. 3 indexed citations

Essner, Ute, et al.. (2022). Effects of SativexⓇ on cognitive function in patients with multiple sclerosis: A systematic review and meta-analysis. Multiple Sclerosis and Related Disorders. 68. 104173–104173. 3 indexed citations

Maleßa, R., et al.. (2021). Nabiximols in Chronic Neuropathic Pain: A Meta-Analysis of Randomized Placebo-Controlled Trials. Pain Medicine. 22(4). 861–874. 34 indexed citations

Ueberall, Michael A., et al.. (2021). Prevalence of drug-induced constipation and severity of associated biopsychosocial effects in patients with nonmalignant pain: a cross-sectional review of depersonalized data from the German Pain e-Registry. Current Medical Research and Opinion. 38(1). 101–114. 3 indexed citations

Ueberall, Michael A., et al.. (2021). Effectiveness, Safety, and Tolerability of Nabiximols Oromucosal Spray vs Typical Oral Long-Acting Opioid Analgesics in Patients with Severe Neuropathic Back Pain: Analysis of 6-Month Real-World Data from the German Pain e-Registry. Pain Medicine. 23(4). 745–760. 8 indexed citations

Überall, Michael A., et al.. (2021). Das PraxisRegister Schmerz - Ausdrucksform kollektiver Intelligenz. Schmerzmedizin. 37(3). 50–54. 1 indexed citations

Meuth, Sven G., et al.. (2020). Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial. International Journal of Neuroscience. 130(12). 1199–1205. 20 indexed citations

Überall, Michael A., R. Maleßa, Herbert Schreiber, Ute Essner, & Gerhard Müller-Schwefe. (2020). Ein kritisches Review zur Evidenz der aktuellen Verschreibungssituation. Schmerzmedizin. 36(5). 40–49. 1 indexed citations

Essner, Ute, et al.. (2019). Effectiveness and tolerability of THC:CBD oromucosal spray as add-on measure in patients with severe chronic pain: analysis of 12-week open-label real-world data provided by the German Pain e-Registry. SHILAP Revista de lepidopterología. 2 indexed citations

10.

Ueberall, Michael A., Ute Essner, & Gerhard Mueller-Schwefe. (2019). <p>Effectiveness and tolerability of THC:CBD oromucosal spray as add-on measure in patients with severe chronic pain: analysis of 12-week open-label real-world data provided by the German Pain e-Registry</p>. Journal of Pain Research. Volume 12. 1577–1604. 48 indexed citations

11.

Akgün, Katja, et al.. (2019). Daily Practice Managing Resistant Multiple Sclerosis Spasticity With Delta-9-Tetrahydrocannabinol: Cannabidiol Oromucosal Spray: A Systematic Review of Observational Studies. SHILAP Revista de lepidopterología. 11. 3701658557–3701658557. 17 indexed citations

12.

Essner, Ute, et al.. (2018). Sativex ^® as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial. International Journal of Neuroscience. 129(2). 119–128. 100 indexed citations

13.

Ueberall, Michael A., Gerhard Mueller-Schwefe, R. Wigand, & Ute Essner. (2016). Efficacy, tolerability, and safety of an oral enzyme combination vs diclofenac in osteoarthritis of the knee: results of an individual patient-level pooled reanalysis of data from six randomized controlled trials. Journal of Pain Research. Volume 9. 941–961. 11 indexed citations

14.

Überall, Michael A., et al.. (2015). Gefahren und Risiken der standardisierten Ersetzung abbruchbedingt fehlender Messwerte in klinischen Analgetikastudien mittels LOCF. MMW - Fortschritte der Medizin. 157(S7). 19–26. 1 indexed citations

15.

Tiel‐Wilck, Klaus, et al.. (2014). Drug-resistant MS spasticity treatment with Sativex^®add-on and driving ability. Acta Neurologica Scandinavica. 131(1). 9–16. 26 indexed citations

16.

Überall, Michael A., Ute Essner, & Gerhard Müller-Schwefe. (2013). [2-week efficacy and tolerability of flupirtine MR and diclofenac in patients with acute low/back pain--results of a post-hoc subgroup analysis of patient-level data from four non-interventional studies].. MMW - Fortschritte der Medizin. 115–123. 6 indexed citations

17.

Zettl, Uwe K., T. Henze, Ute Essner, & Peter Flachenecker. (2013). Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I). The European Journal of Health Economics. 15(9). 953–966. 25 indexed citations

18.

Überall, Michael A., Ute Essner, & Gerhard Müller-Schwefe. (2013). 2-Wochen-Wirksamkeit und -Verträglichkeit von Flupirtin MR und Diclofenac bei akuten Kreuz-/Rückenschmerzen. MMW - Fortschritte der Medizin. 155(S7). 115–123. 2 indexed citations

19.

Henze, T., et al.. (2012). PND54 Fatigue and Quality-of-Life in Multiple Sclerosis Patients With Spasticity in Germany - Results of the Move 1 Study. Value in Health. 15(7). A555–A555. 2 indexed citations

20.

Calabrese, Pasquale, Ute Essner, & Hans Förstl. (2007). Memantine (Ebixa®) in Clinical Practice – Results of an Observational Study. Dementia and Geriatric Cognitive Disorders. 24(2). 111–117. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact